Ksilink https://ksilink.com/ from patient to drug Mon, 23 Feb 2026 17:28:19 +0000 en-US hourly 1 https://ksilink.com/wp-content/uploads/2020/09/cropped-favicon-ksilink-32x32.png Ksilink https://ksilink.com/ 32 32 We are excited about our new collaboration with Oncodesign Presicion Medicine https://ksilink.com/we-are-excited-about-our-new-collaboration-with-oncodesign-presicion-medicine/ Mon, 23 Feb 2026 14:57:41 +0000 https://ksilink.com/?p=7492 L’article We are excited about our new collaboration with Oncodesign Presicion Medicine est apparu en premier sur Ksilink.

]]>

Oncodesign Precision Medicine and Ksilink join forces to test the Nanocyclix® chemical library in cell models derived from patients with serious central nervous system diseases. Please find the press release here

L’article We are excited about our new collaboration with Oncodesign Presicion Medicine est apparu en premier sur Ksilink.

]]> Bio Europe Spring https://ksilink.com/bio-europe-spring/ Mon, 23 Feb 2026 10:55:06 +0000 https://ksilink.com/?p=7495 Interested in our pipeline and platform technologies? Join me in Lisbon for three days of partnering at BIO Europe Spring. We’re actively looking for investors and co‑development partners across our CNS portfolio: – A first‑in‑class, BBB‑penetrant small molecule activating a novel intracellular α‑synuclein clearance mechanism – A human microglia platform enabling patient‑based discovery for neuroinflammation […]

L’article Bio Europe Spring est apparu en premier sur Ksilink.

]]> Interested in our pipeline and platform technologies?

Join me in Lisbon for three days of partnering at BIO Europe Spring.
We’re actively looking for investors and co‑development partners across our CNS portfolio:
– A first‑in‑class, BBB‑penetrant small molecule activating a novel intracellular α‑synuclein clearance mechanism
– A human microglia platform enabling patient‑based discovery for neuroinflammation
– A small‑molecule hit series for Phelan‑McDermid Syndrome, a genetically defined subgroup of Autism Spectrum Disorders
– A versatile discovery platform to accelerate next‑generation, patient‑based drug development programs.

L’article Bio Europe Spring est apparu en premier sur Ksilink.

]]> Meet us at Conferences and Partnerings https://ksilink.com/conferences-and-partnerings-2025/ Tue, 02 Sep 2025 14:25:04 +0000 https://ksilink.com/?p=7362 We’re excited to be present at a series of dynamic conferences, partnering events, and investor meetings throughout the rest of the year. If you’re attending too, don’t hesitate to reach out in advance – we’d love to meet in person, hear about your plans and needs, and share how we’re working to transform drug discovery. […]

L’article Meet us at Conferences and Partnerings est apparu en premier sur Ksilink.

]]> We’re excited to be present at a series of dynamic conferences, partnering events, and investor meetings throughout the rest of the year. If you’re attending too, don’t hesitate to reach out in advance – we’d love to meet in person, hear about your plans and needs, and share how we’re working to transform drug discovery.

Here’s where you can find us:

Symposium 2050, Zurich 4-5 Sept

BiotechX Europe, Basel, 6-8 Oct

Biotech in Europe Forum, Basel, 8-9 Oct

German Stem Cell Network meeting, Munich 15-17 Oct

Orphan Drug Congress Europe, Amsterdam, 28-29 Oct

BioEurope, Vienna, 3-5 Nov

BioFit, Strasbourg, 2-3 Dec

L’article Meet us at Conferences and Partnerings est apparu en premier sur Ksilink.

]]> New publication on phenotypic and transcriptomic characterization, and machine learning-based classification of desmin-related cardiomyopathy disease features https://ksilink.com/new-publication-on-phenotypic-and-transcriptomic-characterization-and-machine-learning-based-classification-of-desmin-related-cardiomyopathy-disease-features/ Tue, 02 Sep 2025 14:23:02 +0000 https://ksilink.com/?p=7403 In collaboration with the Sorbonne University, Ksilink used both patient-derived and genome edited cellular models for desmin-related cardiomyopathy to analyze how the DESE439K mutation disrupts cellular function and contributes to disease phenotypes. Our findings highlighted key phenotypic defects such as cytoplasmic protein aggregation, mitochondrial and sarcomere defects, and contractile dysfunctions. We also developed a machine […]

L’article New publication on phenotypic and transcriptomic characterization, and machine learning-based classification of desmin-related cardiomyopathy disease features est apparu en premier sur Ksilink.

]]> In collaboration with the Sorbonne University, Ksilink used both patient-derived and genome edited cellular models for desmin-related cardiomyopathy to analyze how the DESE439K mutation disrupts cellular function and contributes to disease phenotypes. Our findings highlighted key phenotypic defects such as cytoplasmic protein aggregation, mitochondrial and sarcomere defects, and contractile dysfunctions. We also developed a machine learning prediction model to classify cellular phenotypes, which can be used for drug candidate screening.

Read the full article

L’article New publication on phenotypic and transcriptomic characterization, and machine learning-based classification of desmin-related cardiomyopathy disease features est apparu en premier sur Ksilink.

]]> New publication on morphological map of under- and overexpression of genes in human cells https://ksilink.com/new-publication-on-morphological-map-of-under-and-overexpression-of-genes-in-human-cells/ Tue, 02 Sep 2025 14:17:26 +0000 https://ksilink.com/?p=7401 As a member of the JUMP Cell Painting Consortium, Ksilink contributed to the perturbation of roughly 75% of the protein-coding genome in human U-2 OS cells, generating a rich resource of single-cell images and extracted features. These profiles capture the phenotypic impacts of perturbing 15,243 human genes, including overexpressing 12,609  and knocking out 7,975 genes. […]

L’article New publication on morphological map of under- and overexpression of genes in human cells est apparu en premier sur Ksilink.

]]> As a member of the JUMP Cell Painting Consortium, Ksilink contributed to the perturbation of roughly 75% of the protein-coding genome in human U-2 OS cells, generating a rich resource of single-cell images and extracted features. These profiles capture the phenotypic impacts of perturbing 15,243 human genes, including overexpressing 12,609  and knocking out 7,975 genes. Analysis of phenotypic profiles revealed previously undiscovered gene clusters and functional relationships, including those associated with mitochondrial function, cancer and neural processes.

Read the full article

L’article New publication on morphological map of under- and overexpression of genes in human cells est apparu en premier sur Ksilink.

]]> New publication on morphological profiling revealing neuroprotection in human dopaminergic neurons https://ksilink.com/new-publication-on-morphological-profiling-revealing-neuroprotection-via-mitochondrial-uncoupling-in-human-dopaminergic-neurons/ Fri, 29 Aug 2025 11:55:40 +0000 https://ksilink.com/?p=7370 In collaboration with the University of Luxembourg, Ksilink used a patient-derived cellular model for Parkinson’s Disease based on SNCA triplication and isogenic control mDA neurons to identify and rescue multiple phenotypes. Our pilot screen of > 1000 compounds revealed several compounds restoring healthy phenotypes, increasing Tyrosine hydroxylase (TH) and decreasing α-synuclein (αSyn) levels. Several hits […]

L’article New publication on morphological profiling revealing neuroprotection in human dopaminergic neurons est apparu en premier sur Ksilink.

]]> In collaboration with the University of Luxembourg, Ksilink used a patient-derived cellular model for Parkinson’s Disease based on SNCA triplication and isogenic control mDA neurons to identify and rescue multiple phenotypes. Our pilot screen of > 1000 compounds revealed several compounds restoring healthy phenotypes, increasing Tyrosine hydroxylase (TH) and decreasing α-synuclein (αSyn) levels. Several hits were linked to mitochondrial biology. 

Read the full article

L’article New publication on morphological profiling revealing neuroprotection in human dopaminergic neurons est apparu en premier sur Ksilink.

]]> We are thrilled to announce the arrival of our new Chief Operating Officer! https://ksilink.com/we-are-thrilled-to-announce-the-arrival-of-our-new-chief-operating-officer/ https://ksilink.com/we-are-thrilled-to-announce-the-arrival-of-our-new-chief-operating-officer/#respond Thu, 13 Feb 2025 12:20:38 +0000 https://www.ksilink.com/?p=6390 L’article We are thrilled to announce the arrival of our new Chief Operating Officer! est apparu en premier sur Ksilink.

]]>

Dr Helmut Haning has recently joined the management of Ksilink as COO, complementing the team with a longstanding experience in pharmaceutical drug discovery. He brings to the company a wealth of knowledge and expertise in drug discovery, strategy and operational excellence that will benefit in its future path.
Helmut is also Operating Partner at ARCHIMED, the world leading healthcare Private Equity fund.
In addition, he serves as SVP, Head of Drug Discovery for Metabiopharma in the field of rare genetic and autoimmune diseases.
Helmut started his career as an organic chemist. He joined Bayer, a German pharmaceutical company, in 1995 and subsequently assumed different roles of growing impact and responsibility in the company, retiring as Global Head of Medicinal Chemistry. He is the inventor of a marketed drug and several clinical candidates in different indications. He also build built an early partnering function covering all academic cooperations and early licensing activities. With Metabiopharma, he was successful in identifying a preclinical candidate for a rare genetic disease.

L’article We are thrilled to announce the arrival of our new Chief Operating Officer! est apparu en premier sur Ksilink.

]]> https://ksilink.com/we-are-thrilled-to-announce-the-arrival-of-our-new-chief-operating-officer/feed/ 0 Join Ksilink at BIO Partnering @ JPM Week 2025! https://ksilink.com/bio-partnering-jpm-week-2025/ https://ksilink.com/bio-partnering-jpm-week-2025/#respond Thu, 02 Jan 2025 10:13:52 +0000 https://www.ksilink.com/?p=6374 We are excited to announce that Mona Boyé, Head of BD & Partnerships, and Johannes Wilbertz, Team Leader Neuroscience, will be attending BIO Partnering @ JPM Week in San Francisco from January 13-16, 2025. This event is a leading gathering for the biotechnology industry, offering unparalleled opportunities for networking, partnering, and advancing business development goals. […]

L’article Join Ksilink at BIO Partnering @ JPM Week 2025! est apparu en premier sur Ksilink.

]]> We are excited to announce that Mona Boyé, Head of BD & Partnerships, and Johannes Wilbertz, Team Leader Neuroscience, will be attending BIO Partnering @ JPM Week in San Francisco from January 13-16, 2025. This event is a leading gathering for the biotechnology industry, offering unparalleled opportunities for networking, partnering, and advancing business development goals.

About Ksilink: Ksilink is at the forefront of patient-based drug discovery, designing and applying unique cellular assays for large-scale phenotypic screening. Our proprietary drug discovery engine, powered by AI-driven image analysis, aims to generate the most efficient first-in-class therapeutic molecules for next-generation medicine leveraging our extensive network of academic and clinical partners across Europe.

We look forward to connecting with you in San Francisco to explore new opportunities and collaborations!

L’article Join Ksilink at BIO Partnering @ JPM Week 2025! est apparu en premier sur Ksilink.

]]> https://ksilink.com/bio-partnering-jpm-week-2025/feed/ 0 Ksilink Advances PMDS Research and Disease Modelling https://ksilink.com/ksilink-advances-pmds-research-and-disease-modelling/ https://ksilink.com/ksilink-advances-pmds-research-and-disease-modelling/#respond Tue, 11 Jun 2024 08:05:25 +0000 https://www.ksilink.com/?p=5838 Strasbourg, France – Ksilink, together with our collaborators from I-Stem (Paris), has recently published a scientific paper that provides significant insights into Phelan-McDermid syndrome (PMDS), a genetic disorder that presents complex challenges in neurodevelopment and synaptic function. The research focuses on the SHANK3 gene, which is crucial for the proper development of neural connections. SHANK3 […]

L’article Ksilink Advances PMDS Research and Disease Modelling est apparu en premier sur Ksilink.

]]> Strasbourg, France – Ksilink, together with our collaborators from I-Stem (Paris), has recently published a scientific paper that provides significant insights into Phelan-McDermid syndrome (PMDS), a genetic disorder that presents complex challenges in neurodevelopment and synaptic function.

The research focuses on the SHANK3 gene, which is crucial for the proper development of neural connections. SHANK3 deficiency is a common factor in PMDS, leading to a range of developmental abnormalities. Our study detailed the developmental and synaptic disruptions caused by SHANK3 mutations and used a chemical genomics approach to identify potentially causative cellular pathways.

A key aspect of the research is the identification of small molecular compounds that can address the hyperdifferentiation phenotype seen in SHANK3 deficiency. Among these, one molecule has been highlighted for its ability to positively influence synapse formation and correct neurodevelopmental pathways potentially via influencing cellular actine dynamics.

Ksilink researchers will continue to explore the cellular biology of SHANK3-deficient cells. The identified compounds together with the used cell lines provide a model for understanding the effects of SHANK3 deficiency and hold potential for future development into therapeutic interventions.

Ksilink remains dedicated to advancing the understanding of PMDS and contributing to the broader field of drug discovery. Through continued research and collaboration, we aim to provide valuable models and tools that can aid in the development of effective treatments for PMDS and related disorders.

Our scientific paper can be accessed here: https://rdcu.be/dKnYt

For further details on our research, please visit our website or reach out to us.

L’article Ksilink Advances PMDS Research and Disease Modelling est apparu en premier sur Ksilink.

]]> https://ksilink.com/ksilink-advances-pmds-research-and-disease-modelling/feed/ 0 Artificial Intelligence in Mental Health Summit, July 1st and 2nd, Berlin https://ksilink.com/ai-summit-mental-health-berlin-2024/ https://ksilink.com/ai-summit-mental-health-berlin-2024/#respond Thu, 23 May 2024 14:22:31 +0000 https://www.ksilink.com/?p=5809 Join us for a two-day free event examining the role played by artificial intelligence and digital tools in understanding and supporting mental health. Hosted by the environMENTAL EU Project, Deutsches Zentrum für Psychische Gesundheit (DZPG) and EBRAINS, this event brings together experts within the field of mental health research, practice and policy. More information can […]

L’article Artificial Intelligence in Mental Health Summit, July 1st and 2nd, Berlin est apparu en premier sur Ksilink.

]]> Join us for a two-day free event examining the role played by artificial intelligence and digital tools in understanding and supporting mental health. Hosted by the environMENTAL EU Project, Deutsches Zentrum für Psychische Gesundheit (DZPG) and EBRAINS, this event brings together experts within the field of mental health research, practice and policy.

More information can be found ‘here‘

L’article Artificial Intelligence in Mental Health Summit, July 1st and 2nd, Berlin est apparu en premier sur Ksilink.

]]> https://ksilink.com/ai-summit-mental-health-berlin-2024/feed/ 0